Navigation Links
Evaluating Biomarkers During Clinical Trials for Immunotherapies: A Case Study on the Pioneer Project, Upcoming Webinar Hosted by Xtalks
Date:11/11/2019

Immunotherapies are currently the most rapidly growing drug class and have a major impact in the oncology field. While these approaches have demonstrated impressive results for some patients, important challenges still need to be overcome. Among these, defining valuable and adapted combination protocols, predicting responders to therapies through biomarkers, follow-up or overcoming resistance development to current immunotherapies are major goals to achieve.

The immune microenvironment is one of the factors that critically influences clinical outcome. Therefore, identifying immune-related biomarkers is of crucial importance in the frame of combination therapies with checkpoint inhibitors.

On Wednesday, November 27, 2019 at 11am EST (4pm GMT/UK), join a live webinar where Dr Jérôme Galon, Research Director at Inserm, will explain how biomarker evaluation allows a comprehensive profiling of the tumor and is mandatory to elucidate actionable or resistance mechanisms to treatment in solid cancers. Next, Professor Fabrice Barlesi, Head of Multidisciplinary Oncology and Therapeutic Innovations at APHM, will focus on the choice of relevant immune-related biomarkers to be tested in order to predict and overcome resistance to treatments in patients suffering from lung cancer. The Pioneer Project, supported by the French Research Agency, will illustrate this topic.

This webinar will also include a brief overview of a powerful immuno-oncology platform that can provide meaningful and actionable data through biomarker testing.

For more information or to register for this event, visit Evaluating Biomarkers During Clinical Trials for Immunotherapies: A Case Study on the Pioneer Project.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Read the full story at https://www.prweb.com/releases/evaluating_biomarkers_during_clinical_trials_for_immunotherapies_a_case_study_on_the_pioneer_project_upcoming_webinar_hosted_by_xtalks/prweb16710081.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related medicine technology :

1. New JAMA Report, Initiated by AAAAI and Others, Provides Recommendations for Evaluating and Managing Penicillin Allergy
2. Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 3 Clinical Study Evaluating JZP-258 for the Treatment of Cataplexy and Excessive Daytime Sleepiness in Narcolepsy
3. Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 2 Clinical Study Evaluating JZP-110 for Excessive Sleepiness in Parkinsons Disease
4. Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 3 Clinical Trial Evaluating Defibrotide for the Potential Prevention of VOD in High Risk Patients
5. Jazz Pharmaceuticals Announces That Patient Enrollment is Complete for the Phase 3 Study of JZP-110 Evaluating Excessive Sleepiness in Narcolepsy
6. Debiopharm International SA Initiates Clinical Phase II Study Evaluating Debio 1143 in Ovarian Cancer
7. BTG to Initiate Multi-Centre TARGET Study Evaluating Dosimetry for 90Y Radioembolisation Therapy in Patients With Hepatocellular Carcinoma
8. Encore Vision, Inc. Announces Completion of Target Enrollment in Clinical Study Evaluating Topical EV06 for the Treatment of Presbyopia
9. AbbVie Announces the Launch of Robust Phase 3 Clinical Trial Program Evaluating ABT-494, an Investigational Selective JAK1 Inhibitor, for the Treatment of Rheumatoid Arthritis
10. Halozyme Therapeutics and Eisai to present data evaluating the antitumor effects of PEGPH20 in combination with eribulin mesylate in preclinical breast cancer models
11. Avanir Pharmaceuticals Announces Publication of Study Evaluating the Prevalence of Pseudobulbar Affect (PBA) Symptoms and Use of Antipsychotic Medications in Nursing Homes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2019)... Ariz. (PRWEB) , ... December 06, 2019 , ... ... Industry Nutrition Forum in Philadelphia to share information and ideas about working toward ... of the population. , “It’s vital that we develop a healthy and sustainable ...
(Date:12/6/2019)... ... December 06, 2019 , ... Plant Life ... Garden Supply LLC (a division of Horticultural Holdings LLC) to recommend Plant Life ... , FFGS is a team of disciplined and energetic plant lovers formally ...
(Date:12/5/2019)... ... 05, 2019 , ... Intelligent.com, a trusted resource for online ... Degree Programs for 2020. The comprehensive research guide is based on an assessment ... based on curriculum quality, graduation rate, reputation, and post-graduate employment. , The ...
Breaking Medicine Technology:
(Date:12/6/2019)... (PRWEB) , ... December 06, 2019 , ... ... consistently recognized for its innovations and excellence in patient care. On December 12th, ... standard of excellence at the Health Care Heroes Awards at the Hartford Marriott. ...
(Date:12/6/2019)... ... December 06, 2019 , ... Brain Sentinel, Inc. announces it ... the AES Annual Meeting. The symposium, “Fundamentals of Quantitative Surface Electromyography (sEMG) for ... sEMG analysis during ictal events;, 2. Review specific sEMG patterns of motor seizures ...
(Date:12/5/2019)... ... December 05, 2019 , ... HealthCareMandA.com is ... of Building Platforms— on Thursday, December 12, 2019, at 1:00 PM ET. , ... groups. Middle-market PE firms are scrambling to assemble regional platforms with enough scale ...
(Date:12/4/2019)... ... December 04, 2019 , ... ... Extract®, provides protection from disruptions to cells and tissue and inflammation that leads ... Jet Lag, is available in a dietary supplement product called Prepair™ . ...
(Date:12/4/2019)... (PRWEB) , ... December 04, 2019 , ... ... I study of AZD4041 for treating tobacco use and dependence. The study will ... central nervous system (CNS) penetrant antagonist of orexin-1 (hypocretin-1) receptors that is being ...
Breaking Medicine News(10 mins):